Selective beta-1 blockers deteriorate glucose metabolism. A meta-analysis

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Essential hypertension and type 2 diabetes mellitus (T2DM) are common comorbidities.
• Beta-blockers are frequently prescribed for hypertension, but their effect on glucose metabolism in diabetic patients requires careful consideration.

Purpose of the Study:

• To synthesize available data on the impact of highly selective beta-1 blockers on glucose metabolism.
• To quantify the effect of these agents on glycemic control in patients with both essential hypertension and T2DM using meta-analysis.

Main Methods:

• A comprehensive literature search was conducted in Cochrane Library, PubMed, MEDLINE, and EMBASE databases up to July 2013.
• Randomized controlled trials (RCTs) investigating highly selective beta-1 blockers in hypertensive patients with T2DM were included.
• Meta-analysis was performed using RevMan5.0 software on data from seven trials involving 1354 patients.

Main Results:

• Selective beta-1 blockers were associated with a statistically significant increase in fasting blood glucose (weighted mean difference: 0.21, 95% CI: 0.16-0.27; p<0.00001).
• No significant differences were observed in glycosylated hemoglobin, fasting insulin levels, or body weight gain compared to the control group.

Conclusions:

• Highly selective beta-1 blockers lead to elevated fasting blood glucose levels in patients with essential hypertension and T2DM.
• These findings suggest that selective beta-1 blockers should be used with caution or avoided in patients with coexisting hypertension and type 2 diabetes.